Ipsen, Debiopharm Sign License Agreement
Ipsen and Debiopharm has signed an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.